145 related articles for article (PubMed ID: 21695769)
1. Diversity in diabetes: the role of insulin aspart.
Heller S; McCance DR; Moghissi E; Nazeri A; Kordonouri O
Diabetes Metab Res Rev; 2012 Jan; 28(1):50-61. PubMed ID: 21695769
[TBL] [Abstract][Full Text] [Related]
2. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
3. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
4. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus.
Danne T
Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066
[TBL] [Abstract][Full Text] [Related]
5. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
Balaji V; Balaji MS; Alexander C; Srinivasan A; Suganthi SR; Thiyagarajah A; Seshiah V
Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
[TBL] [Abstract][Full Text] [Related]
6. Insulin aspart: a review.
Owens D; Vora J
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):793-804. PubMed ID: 17014395
[TBL] [Abstract][Full Text] [Related]
7. Premixed insulin treatment for type 2 diabetes: analogue or human?
Garber AJ; Ligthelm R; Christiansen JS; Liebl A
Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
[TBL] [Abstract][Full Text] [Related]
8. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
9. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
Home PD; Hallgren P; Usadel KH; Sane T; Faber J; Grill V; Friberg HH
Diabetes Res Clin Pract; 2006 Feb; 71(2):131-9. PubMed ID: 16054266
[TBL] [Abstract][Full Text] [Related]
10. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes.
Meneilly GS
Diabetes Obes Metab; 2007 Sep; 9(5):754-5. PubMed ID: 17697065
[TBL] [Abstract][Full Text] [Related]
11. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
[TBL] [Abstract][Full Text] [Related]
12. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
[TBL] [Abstract][Full Text] [Related]
13. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
14. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A; Jacobsen LV
Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
[TBL] [Abstract][Full Text] [Related]
17. Insulin analogues: an example of applied medical science.
Sheldon B; Russell-Jones D; Wright J
Diabetes Obes Metab; 2009 Jan; 11(1):5-19. PubMed ID: 19120431
[TBL] [Abstract][Full Text] [Related]
18. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions.
Ando H; Kurita S; Shimizu A; Kato K; Ishikura K; Taji K; Uno M; Takeshita Y; Misu H; Fujimura A; Kaneko S; Takamura T
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):528-34. PubMed ID: 22642657
[TBL] [Abstract][Full Text] [Related]
20. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
